Novel biologics portfolio & partnerships

We generate New Biologic Entities (NBEs) through combining our deep scientific understanding of mechanisms of action with our detailed process knowledge. This expertise has been acquired both through the development of our biosimilar pipeline and our extensive discovery experience at our Utrecht site.

Patient stratification and personalized medicine are the primary focus of our NBE discovery. Besides high scientific merit, availability of companion diagnostics are crucial for the selection of our targets.

Our expression teams design and develop customized screening assays to select the new therapeutic candidates. Our antibody discovery team equipped with our proprietary CASH™ technology and decades of experience in drug development take the step thereafter to show proof of concept.

The extensive expertise of the antibody discovery and development team is illustrated by their involvement in the development of Ibalizumab and our out-licensing agreements with J&J and Argenix.

Our novel biologics pipeline

Target
Therapeutic area
Partner
mAbs developed
Initial proof shown
Cell line development
Undisclosed
Undisclosed
J&J
CD89
Immunology
-
Undisclosed
Oncology
-
Undisclosed
Oncology
-
Undisclosed
Oncology
-
Target Undisclosed
Therapeutic area Undisclosed
Partner J&J
mAbs developed
Initial proof shown
Cell line development
Target CD89
Therapeutic area Immunology
Partner -
mAbs developed
Initial proof shown
Cell line development
Target Undisclosed
Therapeutic area Oncology
Partner -
mAbs developed
Initial proof shown
Cell line development
Target Undisclosed
Therapeutic area Oncology
Partner -
mAbs developed
Initial proof shown
Cell line development
Target Undisclosed
Therapeutic area Oncology
Partner -
mAbs developed
Initial proof shown
Cell line development
  • Program: A novel approach to pathogenic neutrophils
  • Program: Targeting the immune suppressive tumor microenvironment

Project:

Anti-CD89

Partner:

Unpartnered

Therapeutic area:

Immunology

The anti-CD89 program focuses on IgA-mediated diseases and the prevention of IgA-mediated pathogenic neutrophilic damage in tissues. Neutrophils are the most ignored cell type of the immune system and play a devastating role in many auto-immune diseases. Our novel approach is unique in both its target and in its therapeutic potential for neutrophilic diseases, in which treatment options are severely lacking. A significant proportion of auto-immune patients who are not responding to TNF inhibitors have high neutrophil involvement in the disease accompanied by high auto-antigen specific IgA responses.

The candidate antibodies being developed by Polpharma Biologics can prevent the IgA-mediated activation of neutrophils and inhibit the release of chemo-attractive signals and pathogenic molecules, making them unique in their class. Furthermore, for patient stratification and personalized medicine, disease specific companion diagnostics can easily be developed.

Project:

Undisclosed immuno-oncology antibody

Partner:

Unpartnered

Therapeutic area:

Immuno-oncology

Our validated expertise in immunotherapy prompted the discovery and generation of innovative antibodies to new checkpoint inhibitor targets. This target was selected because of its high tumor expression, accompanied by a poor prognosis and immune suppressive tumor microenvironment. Similar to the PD1-PD-L1 axis, tumor expression of our novel target can be used as companion diagnostic for a personalized medicine strategy. This highly selective molecule blocks the regulatory interactions of the target, while leaving the stimulatory capacity untouched.

Let’s collaborate and create quality biologics together.

Get in touch for more information.

We use cookies

Polpharma Biologics uses cookies and other similar technologies (hereinafter: cookies) on its webpages and mobile applications (hereinafter, jointly, Website). The user can manage cookies independently by changing the web browser settings. If you do not consent for your personal data to be collected via cookies, you should change your web browser settings or stop using the Website.

Using the Website without changing the web browser settings indicates your acceptance of the use of cookies by Polpharma. Acceptance of the web browser settings indicates your consent to profiling on the basis of the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect lawfulness of any processing activities carried out under consent before its withdrawal.

For more details see the Cookie Policy.